Publications scientifiques sur le VIH
Data on 52-week safety and efficacy of tesamorelin (TH9507), a growth hormone-releasing factor (GRF) analogue, in HIV-infected patients with abdominal fat accumulation.
2008
Falutz J, Allas S, Mamputu J-C, et al.
Poster #943 presented at: Conference on Retroviruses and Opportunistic Infections; February 3-6, 2008; Boston, Massachusetts, USA.
Long-term safety and efficacy of tesamorelin (TH9507), a growth hormone-releasing factor (GRF) analogue, in HIV-infected patients with abdominal fat accumulation [abstract].
2007
Falutz J, Allas S, Mamputu J-C, et al.
Presented at: 11th European AIDS conference (EACS); October 24-27 2007; Madrid, Spain.
Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue.
2007
Basic Clin Pharmacol Toxicol.
Ferdinandi ES, Brazeau P, High K, et al.
100(1):49-58.
Further data on the effects of tesamorelin (TH9507), a growth hormone-releasing factor analogue, on body composition and metabolic parameters in HIV-infected patients with abdominal fat accumulation [abstract].
2007
Antiviral Therapy
Falutz J, Allas S, Mamputu J-C, et al.
12(suppl 2):L9. Proceedings of the 9th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV.
The impact of tesamorelin (TH9507), a growth hormone-releasing factor analogue, on body image and health-related quality of life in HIV-infected patients with abdominal fat accumulation [abstract].
2007
Antiviral Therapy
Turner RR, Falutz J, Testa MA, et al.
12(suppl 2):L33. Proceedings of the 9th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV.